Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)

详细信息    查看全文

• 作者：Saulius Cicè ; nas^a ; ^{saulius.cicenas@nvi.lt} ; Sarayut Lucien Geater^b ; ^{drgeater@gmail.com} ; Petar Petrov^c ; ^{petar_petrov_doctor@abv.bg} ; Yevgeniy Hotko^d ; ^{yhotko@gmail.com} ; Gregory Hooper^e ; ^{greg.hooper@roche.com} ; Fan Xia^f ; ^{fan.xia@roche.com} ; Nadejda Mudie^g ; ^{nadia.mudie@roche.com} ; Yi-Long Wu^h ; ^{syylwu@live.cn}
• 关键词：First-line erlotinib ; Maintenance erlotinib ; Non-small-cell lung cancer ; Platinum-based chemotherapy
• 刊名：Lung Cancer
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：102
• 期：Complete
• 页码：30-37
• 全文大小：1224 K
• 卷排序：102

文摘

IUNO assessed 1L maintenance vs 2L erlotinib in NSCLC without EGFR mutations. Median OS 9.7 months with ‘early erlotinib’ vs 9.5 months with ‘late erlotinib’. PFS during maintenance treatment was not superior with erlotinib vs placebo. Safety results in IUNO were consistent with the known safety profile of erlotinib.